Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK
ShK, from the sea anemone Stichodactyla helianthus, is a 35-residue disulfide-rich peptide that blocks the voltage-gated potassium channel Kv1.3 at ca. 10 pM and the related channel Kv1.1 at ca. 16 pM. We developed an analog of this peptide, ShK-186, which is currently in Phase 1b-2a clinical tria...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-01-01
|
Series: | Marine Drugs |
Subjects: | |
Online Access: | http://www.mdpi.com/1660-3397/13/1/529 |
id |
doaj-c1c30af770e04c0a8a922513e4d0220d |
---|---|
record_format |
Article |
spelling |
doaj-c1c30af770e04c0a8a922513e4d0220d2020-11-24T20:56:18ZengMDPI AGMarine Drugs1660-33972015-01-0113152954210.3390/md13010529md13010529Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShKMichael W. Pennington0Shih Chieh Chang1Satendra Chauhan2Redwan Huq3Rajeev B. Tajhya4Sandeep Chhabra5Raymond S. Norton6Christine Beeton7Peptides International Inc., 11621 Electron Drive, Louisville, KY 40065, USAMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, AustraliaPeptides International Inc., 11621 Electron Drive, Louisville, KY 40065, USADepartment of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USADepartment of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USAMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, AustraliaMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, AustraliaDepartment of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USAShK, from the sea anemone Stichodactyla helianthus, is a 35-residue disulfide-rich peptide that blocks the voltage-gated potassium channel Kv1.3 at ca. 10 pM and the related channel Kv1.1 at ca. 16 pM. We developed an analog of this peptide, ShK-186, which is currently in Phase 1b-2a clinical trials for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. While ShK-186 displays a >100-fold improvement in selectivity for Kv1.3 over Kv1.1 compared with ShK, there is considerable interest in developing peptides with an even greater selectivity ratio. In this report, we describe several variants of ShK that incorporate p-phophono-phenylalanine at the N-terminus coupled with internal substitutions at Gln16 and Met21. In addition, we also explored the combinatorial effects of these internal substitutions with an alanine extension at the C-terminus. Their selectivity was determined by patch-clamp electrophysiology on Kv1.3 and Kv1.1 channels stably expressed in mouse fibroblasts. The peptides with an alanine extension blocked Kv1.3 at low pM concentrations and exhibited up to 2250-fold selectivity for Kv1.3 over Kv1.1. Analogs that incorporates p-phosphono-phenylalanine at the N-terminus blocked Kv1.3 with IC50s in the low pM range and did not affect Kv1.1 at concentrations up to 100 nM, displaying a selectivity enhancement of >10,000-fold for Kv1.3 over Kv1.1. Other potentially important Kv channels such as Kv1.4 and Kv1.6 were only partially blocked at 100 nM concentrations of each of the ShK analogs.http://www.mdpi.com/1660-3397/13/1/529immunomodulatorT lymphocytepotassium channeldisulfide-rich peptidesea anemone toxinK+ channel blocker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael W. Pennington Shih Chieh Chang Satendra Chauhan Redwan Huq Rajeev B. Tajhya Sandeep Chhabra Raymond S. Norton Christine Beeton |
spellingShingle |
Michael W. Pennington Shih Chieh Chang Satendra Chauhan Redwan Huq Rajeev B. Tajhya Sandeep Chhabra Raymond S. Norton Christine Beeton Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK Marine Drugs immunomodulator T lymphocyte potassium channel disulfide-rich peptide sea anemone toxin K+ channel blocker |
author_facet |
Michael W. Pennington Shih Chieh Chang Satendra Chauhan Redwan Huq Rajeev B. Tajhya Sandeep Chhabra Raymond S. Norton Christine Beeton |
author_sort |
Michael W. Pennington |
title |
Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK |
title_short |
Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK |
title_full |
Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK |
title_fullStr |
Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK |
title_full_unstemmed |
Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK |
title_sort |
development of highly selective kv1.3-blocking peptides based on the sea anemone peptide shk |
publisher |
MDPI AG |
series |
Marine Drugs |
issn |
1660-3397 |
publishDate |
2015-01-01 |
description |
ShK, from the sea anemone Stichodactyla helianthus, is a 35-residue disulfide-rich peptide that blocks the voltage-gated potassium channel Kv1.3 at ca. 10 pM and the related channel Kv1.1 at ca. 16 pM. We developed an analog of this peptide, ShK-186, which is currently in Phase 1b-2a clinical trials for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. While ShK-186 displays a >100-fold improvement in selectivity for Kv1.3 over Kv1.1 compared with ShK, there is considerable interest in developing peptides with an even greater selectivity ratio. In this report, we describe several variants of ShK that incorporate p-phophono-phenylalanine at the N-terminus coupled with internal substitutions at Gln16 and Met21. In addition, we also explored the combinatorial effects of these internal substitutions with an alanine extension at the C-terminus. Their selectivity was determined by patch-clamp electrophysiology on Kv1.3 and Kv1.1 channels stably expressed in mouse fibroblasts. The peptides with an alanine extension blocked Kv1.3 at low pM concentrations and exhibited up to 2250-fold selectivity for Kv1.3 over Kv1.1. Analogs that incorporates p-phosphono-phenylalanine at the N-terminus blocked Kv1.3 with IC50s in the low pM range and did not affect Kv1.1 at concentrations up to 100 nM, displaying a selectivity enhancement of >10,000-fold for Kv1.3 over Kv1.1. Other potentially important Kv channels such as Kv1.4 and Kv1.6 were only partially blocked at 100 nM concentrations of each of the ShK analogs. |
topic |
immunomodulator T lymphocyte potassium channel disulfide-rich peptide sea anemone toxin K+ channel blocker |
url |
http://www.mdpi.com/1660-3397/13/1/529 |
work_keys_str_mv |
AT michaelwpennington developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT shihchiehchang developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT satendrachauhan developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT redwanhuq developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT rajeevbtajhya developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT sandeepchhabra developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT raymondsnorton developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk AT christinebeeton developmentofhighlyselectivekv13blockingpeptidesbasedontheseaanemonepeptideshk |
_version_ |
1716790096395501568 |